Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse
Pauline Charbogne, Brigitte L. Kieffer, Katia Befort
Neuropharmacology (2013) Vol. 76, pp. 204-217
Open Access | Times Cited: 140

Showing 1-25 of 140 citing articles:

The Neuroscience of Drug Reward and Addiction
Nora D. Volkow, Michael Michaelides, Rubén Baler
Physiological Reviews (2019) Vol. 99, Iss. 4, pp. 2115-2140
Open Access | Times Cited: 592
Opioid receptors: drivers to addiction?
Emmanuel Darcq, Brigitte L. Kieffer
Nature reviews. Neuroscience (2018) Vol. 19, Iss. 8, pp. 499-514
Closed Access | Times Cited: 307
Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2
András Váradi, Gina F. Marrone, Travis C. Palmer, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 18, pp. 8381-8397
Open Access | Times Cited: 273
Misuse of Novel Synthetic Opioids: A Deadly New Trend
Matthew P. Prekupec, Peter A. Mansky, Michael H. Baumann
Journal of Addiction Medicine (2017) Vol. 11, Iss. 4, pp. 256-265
Open Access | Times Cited: 255
New psychoactive substances: a review and updates
Abu Shafi, Alex J. Berry, Harry Sumnall, et al.
Therapeutic Advances in Psychopharmacology (2020) Vol. 10
Open Access | Times Cited: 248
Designer drugs: mechanism of action and adverse effects
Dino Luethi, Matthias E. Liechti
Archives of Toxicology (2020) Vol. 94, Iss. 4, pp. 1085-1133
Open Access | Times Cited: 214
The Kappa Opioid Receptor: From Addiction to Depression, and Back
Laurence Lalanne, Gülebru Ayrancı, Brigitte L. Kieffer, et al.
Frontiers in Psychiatry (2014) Vol. 5
Open Access | Times Cited: 206
Fulfilling the Promise of "Biased" G Protein–Coupled Receptor Agonism
Louis M. Luttrell, Stuart Maudsley, Laura Bohn
Molecular Pharmacology (2015) Vol. 88, Iss. 3, pp. 579-588
Open Access | Times Cited: 180
Genetic studies of alcohol dependence in the context of the addiction cycle
Matthew T. Reilly, Antonio Noronha, David Goldman, et al.
Neuropharmacology (2017) Vol. 122, pp. 3-21
Open Access | Times Cited: 140
Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies
Befort Katia
Frontiers in Pharmacology (2015) Vol. 6
Open Access | Times Cited: 113
Molecular Pharmacology ofδ-Opioid Receptors
Louis Gendron, Catherine M. Cahill, Mark von Zastrow, et al.
Pharmacological Reviews (2016) Vol. 68, Iss. 3, pp. 631-700
Open Access | Times Cited: 108
Synthesis, Chemical Characterization, and μ-Opioid Receptor Activity Assessment of the Emerging Group of “Nitazene” 2-Benzylbenzimidazole Synthetic Opioids
Marthe M. Vandeputte, Katleen Van Uytfanghe, Nathan K. Layle, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 7, pp. 1241-1251
Open Access | Times Cited: 98
Targeting opioid dysregulation in depression for the development of novel therapeutics
Caroline A. Browne, Irwin Lucki
Pharmacology & Therapeutics (2019) Vol. 201, pp. 51-76
Open Access | Times Cited: 84
Comparative neuropharmacology of structurally distinct non-fentanyl opioids that are appearing on recreational drug markets worldwide
Marthe M. Vandeputte, Meng-Hua M. Tsai, Li Chen, et al.
Drug and Alcohol Dependence (2023) Vol. 249, pp. 109939-109939
Closed Access | Times Cited: 23
In vitro structure–activity relationships and forensic case series of emerging 2-benzylbenzimidazole ‘nitazene’ opioids
Liam M. De Vrieze, Sara E. Walton, Eline Pottie, et al.
Archives of Toxicology (2024) Vol. 98, Iss. 9, pp. 2999-3018
Open Access | Times Cited: 12
Expression of mu opioid receptor in dorsal diencephalic conduction system: New insights for the medial habenula
Olivier Gardon, Lauren Faget, Paul Chu Sin Chung, et al.
Neuroscience (2014) Vol. 277, pp. 595-609
Open Access | Times Cited: 88
The effects of Beta-Endorphin: state change modification
Jan G. Veening, Henk Barendregt
Fluids and Barriers of the CNS (2015) Vol. 12, Iss. 1, pp. 3-3
Open Access | Times Cited: 76
Recent advances on the δ opioid receptor: from trafficking to function
Louis Gendron, Nitish Mittal, Hélène Beaudry, et al.
British Journal of Pharmacology (2014) Vol. 172, Iss. 2, pp. 403-419
Open Access | Times Cited: 75
The Negative Affect of Protracted Opioid Abstinence: Progress and Perspectives From Rodent Models
Lola Welsch, Julie Bailly, Emmanuel Darcq, et al.
Biological Psychiatry (2019) Vol. 87, Iss. 1, pp. 54-63
Open Access | Times Cited: 69
Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1
Dana B. Hancock, Joshua L. Levy, Nathan Gaddis, et al.
Biological Psychiatry (2015) Vol. 78, Iss. 7, pp. 474-484
Open Access | Times Cited: 68
Non-nociceptive roles of opioids in the CNS: opioids’ effects on neurogenesis, learning, memory and affect
Cherkaouia Kibaly, Chi Xu, Catherine M. Cahill, et al.
Nature reviews. Neuroscience (2018) Vol. 20, Iss. 1, pp. 5-18
Open Access | Times Cited: 67
Mu Opioid Receptors in Gamma-Aminobutyric Acidergic Forebrain Neurons Moderate Motivation for Heroin and Palatable Food
Pauline Charbogne, Olivier Gardon, Elena Martín‐García, et al.
Biological Psychiatry (2016) Vol. 81, Iss. 9, pp. 778-788
Open Access | Times Cited: 65
Mu opioid receptors in the medial habenula contribute to naloxone aversion
Laura‐Joy Boulos, Sami Ben Hamida, Julie Bailly, et al.
Neuropsychopharmacology (2019) Vol. 45, Iss. 2, pp. 247-255
Open Access | Times Cited: 59
Genetic behavioral screen identifies an orphan anti-opioid system
Dandan Wang, Hannah M. Stoveken, Stefano Zucca, et al.
Science (2019) Vol. 365, Iss. 6459, pp. 1267-1273
Open Access | Times Cited: 56
A ghrelin receptor (GHS-R1A) antagonist attenuates the rewarding properties of morphine and increases opioid peptide levels in reward areas in mice
Jörgen A. Engel, Ingrid Nylander, Elisabet Jerlhag
European Neuropsychopharmacology (2015) Vol. 25, Iss. 12, pp. 2364-2371
Open Access | Times Cited: 58
Page 1 - Next Page

Scroll to top